Erasca priced an upsized public offering of 22.5 million shares at $10.00 per share, generating expected gross proceeds of about $225 million and granting underwriters a 30‑day option on additional shares. The company, focused on RAS/MAPK‑driven cancers, said proceeds will support clinical development and corporate operations. The financing follows an earlier filing for a proposed $150 million offering; the two disclosures together signal Erasca’s push to shore up capital for mid‑ and late‑stage studies. Management set the expected close in late January and noted customary underwriting discounts and closing conditions. Biotech investors will watch how Erasca deploys proceeds across its precision‑oncology portfolio and whether planned data readouts and program milestones translate into further funding or partnership options.